Journal Article
Review
Add like
Add dislike
Add to saved papers

An up-date on newly discovered immunohistochemical biomarkers for the diagnosis of human testicular germ cell tumors.

Although testicular germ cell tumors (TGCTs) are relatively uncommon, they are particularly important, as they tend to affect children and young men, the most common tumor being in males aged from 20 to 40 years, and the incidence has been increasing in the last years. TGCTs comprise two major histologic groups: seminomas and non-seminomas germ cell tumors (NSGCTs). NSGCTs can be further divided into embryonal, carcinoma, Teratoma, yolk sac tumor, and choriocarcinoma. Seminomas and NSGCTs present significant differences in clinical features, therapy, and prognosis, and both show characteristics of the Primordial Germ Cells (PGCs). For proper diagnosis of the different histological subgroups, immunohistochemistry is required using different molecular markers, such as Aurora B, GPR30, Nek2, HMGA1, HMGA2, and others, and they could represent useful novel molecular targets for antineoplastic strategies. More insight into the pathogenesis of TGCTs is likely to contribute not only to better treatment of these tumors but also to a better understanding of stem cells and oncogenesis.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app